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A B S T R A C T   
Background: Buprenorphine is abused in several countries notwithstanding its benefits as an analgesic and as an 
opioid agonist treatment medication. Benzodiazepines and alcohol have previously been associated with 
buprenorphine toxicity. This study elucidates the role of emerging concomitant drugs in different groups of 
buprenorphine user deaths. 
Methods: All cases in the Finnish national post-mortem toxicology database from 2016–2019 in which bupre-
norphine or norbuprenorphine was a laboratory finding in any post-mortem specimen and age at death of 15–64 
years were investigated for cause and manner of death, concurrent drug and alcohol findings, age, and gender. 
Results: There were 792 deaths with a buprenorphine finding, of which buprenorphine was implicated in 
poisoning without other opioids in 271 cases (34 %). In this group of buprenorphine poisoning deaths, 
concomitant benzodiazepines were found in 94 % (clonazepam 53 %), illicit drugs in 63 %, gabapentinoids in 50 
% (pregabalin 41 %), alcohol in 41 %, antidepressants in 32 %, and antipsychotics in 28 % of cases; only three 
deaths showed no benzodiazepines, alcohol, or gabapentinoids. Polydrug use was common regardless of the 
cause of death. In the age group 15 to 24 years, concomitant use of benzodiazepines and illicit drugs, and 
buprenorphine poisoning were more prevalent than in the age group 25–64 years. 
Conclusions: The unprecedentedly high concomitant use of benzodiazepines in buprenorphine user deaths ob-
scures other possible pharmacological risk factors for buprenorphine poisoning that could be relevant for pre-
vention. Higher mortality in the younger age group suggests particularly unsafe drug use patterns that should be 
addressed.   
1. Introduction 
Buprenorphine is a semi-synthetic opioid and is used to treat 
moderate-to-severe and usually chronic pain. It is a common medication 
for opioid use disorder patients in opioid agonist treatment (OAT), 
which aims to minimize the social and health harms related to opioid 
abuse. 
Buprenorphine is a weak partial μ-opioid receptor agonist and a 
weak κ -opioid receptor antagonist. The drug has a higher affinity, but 
lower intrinsic activity compared to full μ-opioid agonists, such as 
methadone. Buprenorphine preferentially binds to the opioid receptor 
and displaces lower affinity opioids without activating the receptor to a 
similar extent. Respiratory depression is a serious adverse effect of 
opioids that can lead to coma and death. Due to the properties described 
above, buprenorphine exhibits clinically slow onset of action and ceiling 
respiratory effects, supporting its safety profile compared to other opi-
oids. Buprenorphine dissociates from opioid receptors very slowly, 
resulting in a long duration of action (Jasinski et al., 1978; Walsh et al., 
1995; Yassen et al., 2007; Davis et al., 2018). 
OAT is mostly performed with buprenorphine or methadone and the 
treatment is associated with lower rates of overdose death and all-cause 
mortality (Clausen et al., 2009; Degenhardt et al., 2011; White et al., 
2015). Marteau et al. investigated the relative safety of buprenorphine 
and methadone for OAT and observed that buprenorphine is six times 
safer than methadone with regard to overdose risk among the general 
population (Marteau et al., 2015). In 2015, 63 % of Finnish OAT patients 
received buprenorphine and 37 % received methadone (EMCDDA, 
2019a). Despite the benefits of buprenorphine OAT, the drug is associ-
ated with abuse and diversion. Substantial buprenorphine abuse has 
been reported in several countries, including Australia, Finland, France, 
Sweden, and USA (Yokell et al., 2011; Li et al., 2016). In Finland, reports 
of high-dose buprenorphine abuse date back to the late 1990s and 
coincide with the initiation of OAT. 
Several studies have addressed the significant role of buprenorphine 
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in the Finnish drug scene (Uosukainen et al., 2013a, b; Uosukainen et al., 
2014; Launonen et al., 2016; Kauhanen and Tiihonen, 2017). Finland 
has an opioid abuse profile different from the neighboring Nordic 
countries, with a very limited supply of heroin and less methadone 
abuse. Buprenorphine accounts for about one third of the total drug 
poisoning mortality (5.84 per 100,000 for inhabitants aged 15–64 in 
2017) (Simonsen et al., 2020). Uosukainen et al. studied clients seeking 
treatment for buprenorphine abuse and found that daily buprenorphine 
abuse, intravenous administration, and concurrent substance use were 
common (Uosukainen et al., 2013a). 
A large proportion of opioid-dependent people in Finland started 
their opioid use with buprenorphine purchased directly from the street 
trade. Buprenorphine addiction is a particularly Finnish problem, as 
more than 80 % of high-risk opioid users have used buprenorphine as 
their main drug (Kauhanen and Tiihonen, 2017). The abused bupre-
norphine is predominantly diverted pharmaceutical grade 
mono-buprenorphine tablets smuggled into the country from abroad, 
especially from France (Finnish Customs, 2018). 
OAT based on buprenorphine is often implemented using a sublin-
gual combination product containing buprenorphine and naloxone. The 
opioid antagonist naloxone in the coformulation should prevent 
parenteral use of the product but allow sublingual dosing. Naloxone acts 
as a full antagonist for opioid receptors, thus reducing the likelihood of 
parenteral use, including intravenous and nasal administration (Orman 
and Keating, 2009). With the exception of pregnant women treated with 
mono-buprenorphine, buprenorphine/naloxone has been the sole 
buprenorphine product for treating OAT patients in Finland since 2007 
until 2018, after which a prolonged-release subcutaneous buprenor-
phine injection treatment has been initiated for a growing proportion of 
patients. Buprenorphine/naloxone also has intravenous abuse potential, 
although the potential is lower than with buprenorphine alone (Comer 
et al., 2002; Alho et al., 2007); the combination product is equally liable 
to cause fatal poisonings (Häkkinen et al., 2013; Kriikku et al., 2018). 
Differences in blood concentrations of buprenorphine or its metab-
olite norbuprenorphine between buprenorphine-induced deaths and 
cases with other causes of death are not clinically relevant (Häkkinen 
et al., 2012; Seldén et al., 2012), suggesting that explanatory factors 
other than plain buprenorphine overdose exist. Following early obser-
vations on the involvement of concomitant drugs (Tracqui et al., 1998), 
there is increasing evidence that buprenorphine-related fatalities are 
associated with the use of central nervous system depressants, such as 
alcohol and benzodiazepines, which potentiate respiratory depression 
(Mégarbane et al., 2006; Ferrant et al., 2011; Jones et al., 2012; 
Häkkinen et al., 2012; Seldén et al., 2012). Despite the widely recog-
nized problem of concurrent use of sedative/hypnotic drugs among 
people who use drugs, our understanding of the factors incidental to 
fatal buprenorphine-related deaths is still limited (Wightman et al., 
2020). 
Although the rates of fatal and non-fatal opioid overdose have been 
extensively studied among patients receiving OAT (Gibson and Degen-
hardt, 2007; Wikner et al., 2014; Kelty and Hulse, 2017; Abrahamsson 
et al., 2017; Sordo et al., 2017), less information is available from the 
perspective of cause-of-death determination of people who use drugs. In 
the present study, we assess recent trends in buprenorphine-related 
deaths in Finland by focusing on the deceased buprenorphine users’ 
age distribution and polydrug use during the 4-year period of 
2016–2019, with a special emphasis on the young age group 15–24 
years. In addition to concomitant benzodiazepines and alcohol, the 
prevalence of emerging psychoactive drugs, such as the gabapentinoids 
pregabalin and gabapentin, is elucidated in detail, taking advantage of 
the comprehensive post-mortem toxicology investigation and the 
extensive national cause-of-death register available. 
2. Materials and methods 
2.1. Data collection 
All sudden and unexpected deaths in Finland are investigated with a 
medico-legal autopsy initiated by the police and performed by a forensic 
pathologist. These include fatalities unexplained by disease or related to 
accidents, crime, suicide, poisoning, occupational disease, medical 
procedure, or war. Approximately 16 % of all deaths undergo a medico- 
legal investigation. In approximately 75 % of autopsy cases, a compre-
hensive post-mortem toxicology investigation is conducted by request of 
the forensic pathologist (12 % of all deaths). The research material 
included the forensic pathologist’s referral, a brief description of the 
circumstances of death, the main autopsy findings, comprehensive lab-
oratory analysis results, and information extracted from the death cer-
tificate (time of death, age, gender, cause of death, manner of death). 
This was a retrospective study that consisted of all medico-legal 
autopsy cases of deceased persons aged 15–64 years in Finland from 
2016–2019 with a buprenorphine or norbuprenorphine finding in any 
analyzed autopsy specimen (blood, urine, vitreous humor, liver, mus-
cle). Two unidentified subjects were excluded. 
In total, the study included 792 subjects who were divided into the 
following four groups by the authors: 
Group A: Buprenorphine implicated in poisoning (i.e. the forensic 
pathologist had recorded buprenorphine in the death certificate as 
either the main cause or a secondary cause of fatal poisoning) without 
other opioids 
Group B: Buprenorphine implicated in poisoning with other opioids; 
Group C: Other poisoning, in which buprenorphine was a laboratory 
finding, but not implicated in the causes of death; and 
Group D: Controls, in which buprenorphine was a laboratory finding 
but poisoning was not the cause of death. 
2.2. Statistical analysis 
All statistical analyses were performed using the Statistical Package 
for Social Sciences (SPSS version 26.0, IBM Inc., USA). 
Medians were used to characterize the data since the values within a 
group were not normally distributed. The analysis of categorical vari-
ables (such as age, gender, and number of other drugs used) was per-
formed using the nonparametric Kruskall-Wallis test followed by the 
multiple comparison test (Dunn’s test). A p-value of < 0.05 was 
considered statistically significant for all analyses. 
2.3. Ethical issues 
The study was carried out on the basis of the research permit THL/ 
1922/6.02.00/2017, issued by the Finnish Institute for Health and 
Welfare, Finland. According to the Finnish legislation, no separate 
ethical approval is needed for studies that utilize de-identified register- 
based data (Personal Data Act 523/1999). 
3. Results 
Buprenorphine or norbuprenorphine was detected in 792 post- 
mortem investigations involving deceased persons aged 15–64 years in 
Finland during the 4-year study period of 2016–2019 (hereafter referred 
to as buprenorphine user deaths). Table 1 shows the number of cases, 
median age, manner of death, and the proportion of individuals aged 
15–24 years in each of the four groups (A–D) and in the entire study 
population. Group C consisted of poisoning cases as follows: drugs other 
than buprenorphine (N = 73, 85 %), ethanol (N = 8, 9%), carbon 
monoxide (N = 4, 5%), and methanol (N = 1, 1%). 
Fig. 1 shows the annual numbers of all buprenorphine user deaths 
and separately the numbers for individuals aged 15–25 years. Of all 
deceased persons in the study, 84 % were male. The proportion of 
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females was 20 %, 9%, 19 %, and 15 % in groups A to D, respectively. 
There were no significant differences in the proportion of females in the 
groups (p = 0.097). 
The overall number of buprenorphine user deaths increased over the 
study period from 170 cases in 2016 to 217 cases in 2019. The increase 
was mainly due to group A, as the proportion of group A deaths 
increased from 27.6 % in 2016 to 42.4 % in 2019. In the age group 
15–24 years, the proportion of group A deaths increased from 39.1 % in 
2016 to 68.8 % in 2019. There were significantly more individuals aged 
15–24 years in group A than in any of the other groups (p < 0.05). Of all 
deceased individuals aged 15–24 years, 52 % were in group A, 13 % in 
group B, 7.9 % in group C, and 27 % in group D. 
Fig. 2 illustrates the number of buprenorphine user deaths divided 
into 5-year age groups. The median ages in each group are shown in 
Table 1. The median age was significantly lower in group A when 
compared to the other groups (p < 0.001). 
Concomitant alcohol and drug findings in all buprenorphine user 
deaths are shown in Fig. 3 and in detail in Table 2. The average number 
of concomitant drugs per death case was 4.7, 6.4, 5.2, and 4.2 in groups 
A to D, respectively. All drugs included in the database search are shown 
in supplementary Table 1S. 
Blood alcohol concentration was significantly more often above the 
laboratory cut-off (0.2 g/kg) in groups A (p < 0.001) and C (p < 0.05) 
than in group D. Groups A and B had significantly more deaths with a 
concomitant benzodiazepine finding than group D (p = 0.001 and p <
0.001, respectively). Other opioids were significantly more often found 
in group B than in groups C and D (p < 0.001). Gabapentinoids were 
significantly more often found in groups B and A than in group D (p <
0.05 and p < 0.001, respectively). Pregabalin was significantly more 
often found in group B than in any other group (p < 0.05). Pregabalin 
was more prevalent in group A than in group D (p < 0.001). There were 
no significant differences in the prevalence of antidepressants, antipsy-
chotics, illicit drugs and new psychoactive substances, or other medic-
inal drugs between groups A to D (p > 0.05). 
Buprenorphine and alcohol without other drugs were found in six 
cases (0.8 %); three cases (1%) were in group A, one case (1%) in group 
C, and two cases (0.6 %) in group D. 
In group A, among the 255 benzodiazepine positive cases, one (41 
%), two (39 %), or three (13 %) different benzodiazepines were found. 
Respectively, in group B, among 93 cases, two (47 %), three (23 %), or 
one (17 %) benzodiazepines were found; in group C, among 75 cases, 
Table 1 
Number of cases, median ages with interquartile ranges (IQR), and the proportion of different manners of death in all buprenorphine user deaths and in age group 15- 
24 years for each user group A-D in Finland in 2016-2019.  
Group N (%) Median age Manner of death N (%), age group   
IQR), years N (%), accident N (%), suicide N (%), undetermined N (%), other* 15− 24 years 
A All 271  31 (23¡39) 245 (90) 13 (5) 13 (5) – – 79 (29)  
Males 218 (80) 32 (25− 39) 202 (93) 8 (4) 8 (4) – – 53 (24)  
Females 53 (20) 26 (19− 37) 43 (81) 5 (9) 5 (9) – – 26 (49) 
B All 99  36 (26¡42) 88 (89) 3 (3) 8 (8) – – 20 (20)  
Males 90 (91) 36 (26− 42) 79 (88) 3 (3) 8 (9) – – 18 (20)  
Females 9 (9) 39 (25− 43) 9 (100) – – – – – – 2 (22) 
C All 86  34 (27¡43) 61 (71) 14 (16) 11 (13) – – 12 (14)  
Males 70 (81) 37 (27− 44) 52 (74) 9 (13) 9 (13) – – 7 (10)  
Females 16 (19) 30 (24− 34) 9 (56) 5 (31) 2 (13) – – 5 (31) 
D All 336  36 (28¡47) 46 (14) 71 (21) 13 (4) 206 (61) 41 (12)  
Males 284 (85) 36 (29− 46) 42 (15) 62 (22) 11 (4) 169 (60) 31 (11)  
Females 52 (15) 34 (27− 50) 4 (8) 9 (17) 2 (4) 37 (71) 10 (19) 
All All 792  34 (26¡43) 440 (56) 101 (13) 45 (6) 206 (26) 152 (19)  
Males 662 (84) 35 (27− 43) 375 (57) 82 (12) 36 (5) 169 (26) 109 (16)  
Females 130 (16) 30 (23− 43) 65 (50) 19 (15) 9 (7) 37 (28) 43 (33) 
Group A: Buprenorphine implicated in poisoning without other opioids. 
Group B: Buprenorphine implicated in poisoning with other opioids. 
Group C: Other poisoning, in which buprenorphine was a laboratory finding, but not implicated in the causes of death. 
Group D: Controls, in which buprenorphine was a laboratory finding but poisoning was not the cause of death. 
* Other manners of death included the following (N): disease (174), homicide (29), war (1), medical treatment (1), and occupational disease (1). 
Fig. 1. Annual number of buprenorphine user deaths for each user group A-D 
in (a) all age groups and (b) in age group 15-24 years in Finland in 2016-2019. 
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one (41 %) or two (37 %) benzodiazepines were found; in group D, 
among 272 cases, one (37 %), two (29 %) or three (11 %) benzodiaze-
pines were found. Buprenorphine and a benzodiazepine without other 
drugs or alcohol were found in 24 cases (3%); 11 cases (4%) were in 
group A and 13 cases (4%) in group D. 
Both pregabalin and gabapentin were present in 45 cases (6%); 14 
cases (5%) were in group A, 12 (12 %) in group B, 5 (6%) in group C, and 
14 (4%) in group D. Buprenorphine and a gabapentinoid without other 
drugs or alcohol were found in one case (0.1 %; pregabalin in group D). 
Table 3 compares the concomitant use of alcohol, benzodiazepines, 
gabapentinoids, and illicit and new psychoactive substances between 
the age groups 15–24 and 25–64 years. Concomitant use of benzodiaz-
epines and illicit and new psychoactive substances was significantly 
more common in the age group 15–24 years than in 25–64 years (p =
0.001). Alcohol was more often used in the age group 25–64 years but 
the difference was not significant (p = 0.109). In the age group 15–24 
years, there were no significant differences in the concomitant use of 
alcohol, benzodiazepines, gabapentinoids, or illicit and new psychoac-
tive substances between the buprenorphine user groups A to D (p >
0.05). 
In the age group 25–64 years, concomitant use of benzodiazepines 
was significantly more common in groups A and B than in group D (p <
0.001 and p = 0.003, respectively). Gabapentinoids were most 
commonly detected in group B; the difference was significant with all 
other user groups (p < 0.05). Alcohol was most commonly detected in 
group A; the difference was significant when compared to groups B and 
D (p < 0.05 and p < 0.001, respectively). 
Of all 792 buprenorphine user deaths, buprenorphine alone was 
considered the main cause of fatal poisoning in 28 cases (4%). However, 
there were no cases with buprenorphine as the only toxicological 
finding. In group A, there were three (1%) cases in which benzodiaze-
pines, alcohol, pregabalin, or gabapentin were not present. These cases 
are described in more detail below.  
- Case 1. A 23-year-old female suffering from unstable personality 
disorder and psychotic symptoms had used alcohol, buprenorphine, 
cannabis, and ecstasy with her friends in the evening. In the morning, 
she was found dead in her bed. She had a history of using various 
Fig. 2. Age distribution of buprenorphine user deaths.  
Fig. 3. Concomitant findings of alcohol and classes of drug in buprenorphine user deaths.  
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intoxicants and had had previous emergency department visits due 
to poisoning symptoms. Toxicology findings in blood were bupre-
norphine (1.2 μg/L), MDMA (0.88 mg/L), MDA (0.09 mg/L), THC 
(1.6 μg/L), THC-COOH (10 μg/L), levomepromazine (0.88 mg/L), 
sertraline (0.24 mg/L), quetiapine (0.40 mg/L), valproic acid (22 
mg/L), and caffeine (6.4 mg/L). Accidental poisoning from MDMA, 
buprenorphine, and levomepromazine was determined as the cause 
of death, with cardiomegaly as a contributing factor.  
- Case 2. A 23-year-old obese woman suffering from type 2 diabetes 
mellitus, depression, and panic disorder had been drinking alcohol 
during the evening and night. She had fallen out of her bed at home 
and was subsequently found lifeless. She died despite resuscitation 
Table 2 
Concomitant findings of alcohol and different drugs in buprenorphine user deaths.  
Substance Group A (N = 271) Group B (N = 99) Group C (N = 86) Group D (N = 336)  
N (%) N (%) N (%) N (%) 
Alcohol 112 (41) 32 (32) 33 (38) 80 (24) 
Antidepressants 88 (32) 31 (31) 34 (40) 99 (29) 
Amitriptyline/nortriptyline 8 (3) 9 (9) 11 (13) 16 (5) 
Bupropion 7 (3) 2 (2) 9 (10) 9 (3) 
Citalopram 28 (10) 7 (7) 6 (7) 17 (5) 
Mirtazapine 28 (10) 16 (16) 6 (7) 37 (11) 
Venlafaxine 16 (6) 3 (3) 4 (5) 17 (5) 
Antipsychotics 77 (28) 25 (25) 18 (21) 70 (21) 
Levomepromazine 17 (6) 8 (8) 4 (5) 6 (2) 
Olanzapine 19 (7) 5 (5) 6 (7) 21 (6) 
Quetiapine 47 (17) 13 (13) 7 (8) 40 (12) 
Benzodiazepines 255 (94) 93 (94) 75 (87) 272 (81) 
Alprazolam 100 (37) 42 (42) 25 (29) 86 (26) 
Chlordiazepoxide 8 (3) 6 (6) 4 (5) 6 (2) 
Clonazepam 144 (53) 62 (63) 32 (37) 149 (44) 
Diazepam 93 (34) 56 (57) 33 (38) 123 (37) 
Midazolam 13 (5) 8 (8) 4 (5) 18 (5) 
Oxazepam 22 (8) 8 (8) 9 (10) 28 (8) 
Temazepam 19 (7) 7 (7) 5 (6) 34 (10) 
Zopiclone 8 (3) 4 (4) 4 (5) 8 (2) 
Gabapentinoids 136 (50) 64 (65) 35 (41) 114 (34) 
Gabapentin 39 (14) 22 (22) 13 (15) 38 (11) 
Pregabalin 111 (41) 54 (55) 27 (31) 90 (27) 
Illicit drugs and NPS 170 (63) 71 (72) 49 (57) 195 (58) 
alpha-PVP 6 (2) 3 (3) 4 (5) 3 (1) 
Amphetamine/methamphetamine 125 (46) 51 (52) 38 (44) 145 (43) 
Cocaine 7 (3) 6 (6) 6 (7) 11 (3) 
GHB 3 (1) 3 (3) 4 (5) 6 (2) 
MDMA 58 (21) 10 (10) 15 (17) 30 (9) 
THC-COOH 118 (44) 44 (44) 26 (30) 126 (38) 
Opioids –  99 (100) 48 (56) 100 (30) 
Codeine –  26 (26) 14 (16) 28 (8) 
Fentanyl –  7 (7) 9 (10) 7 (2) 
Methadone –  17 (17) 7 (8) 17 (5) 
Morphine –  7 (7) 1 (1) 5 (1) 
Oxycodone –  22 (22) 9 (10) 24 (7) 
Tramadol –  32 (32) 18 (21) 44 (13) 
U-47,700 –  2 (2) 4 (5) 0 (0) 
Other drugs 33 (12) 15 (15) 13 (15) 51 (15) 
Hydroxyzine 9 (3) 7 (7) 6 (7) 22 (7) 
Methylphenidate 11 (4) 5 (5) 3 (3) 12 (4) 
Footnote. NPS = new psychoactive substances. 
Table 3 
Concomitant findings of alcohol and drugs in buprenorphine user deaths with average number of concomitant drugs per death case in age groups 15-24 and 25-64 
years.   
Alcohol Benzodiazepines Gabapentinoids Illicit drugs and NPS  
N (%) N (%) Average findings/case N (%) Average findings/case N (%) Average findings/case 
Group A (N ¼ 271)            
15− 24 years 22 (28) 77 (97) 1.8 38 (48) 0.5 61 (77) 1.7 
25− 64 years 90 (47) 178 (93) 1.6 98 (51) 0.6 109 (57) 1.0 
Group B (N ¼ 99)            
15− 24 years 5 (25) 20 (100) 2.1 11 (55) 0.7 18 (90) 1.4 
25− 64 years 27 (34) 73 (92) 5.1 53 (67) 0.8 53 (67) 1.2 
Group C (N ¼ 86)            
15− 24 years 6 (50) 11 (92) 1.8 6 (50) 0.5 9 (75) 1.2 
25− 64 years 27 (36) 64 (86) 1.4 29 (39) 0.5 40 (54) 1.1 
Group D (N ¼ 336)            
15− 24 years 8 (20) 38 (93) 1.8 15 (37) 0.5 28 (68) 1.2 
25− 64 years 72 (24) 234 (79) 1.4 99 (34) 0.1 167 (57) 0.9 
Footnote. NPS = new psychoactive substances. 
C. Mariottini et al.                                                                                                                                                                                                                              
Drug and Alcohol Dependence 218 (2021) 108345
6
measures. Toxicology findings in blood were buprenorphine (0.58 
μg/L) and citalopram (< 0.1 mg/L). Toxicology findings in urine 
were buprenorphine (81 μg/L), norbuprenorphine (38 μg/L), 
naloxone (120 mg/L) and ethyl glucuronide (53 mg/L). Buprenor-
phine poisoning (manner of death undetermined) was determined as 
the cause of death, with morbid obesity as a contributing factor.  
- Case 3. A 43-year-old epileptic man was found dead at home lying 
prone on the coach. He was known to have used cannabis and also 
drugs in excess of therapeutic doses. Toxicology findings in blood 
were buprenorphine (4.4 μg/L), norbuprenorphine (5.3 μg/L), THC 
(20 μg/L), THC-COOH (230 μg/L), and 11-hydroxy-THC (12 μg/L). 
Toxicology findings in urine were buprenorphine (> 200 μg/L), 
norbuprenorphine (130 μg/L), THC-COOH (3300 μg/L), and chlor-
cyclizine (posit.). Accidental buprenorphine poisoning was deter-
mined as the cause of death. 
4. Discussion 
Of all buprenorphine user deaths, buprenorphine was implicated in a 
poisoning without other opioids in 34 % (group A) and with other opi-
oids in 13 % of cases (group B); the proportion of other than 
buprenorphine-related poisonings was 11 % (group C) and non- 
poisonings 42 % (group D). 
Our research corroborates the previous findings of a high level of 
concomitant drug use in buprenorphine-related deaths. In group A 
buprenorphine poisonings, concomitant benzodiazepines were found in 
94 %, illicit drugs in 63 %, gabapentinoids in 50 %, alcohol in 41 %, 
antidepressants in 32 %, and antipsychotics in 28 % of cases. In a pre-
vious Finnish study from 2000 to 2008, Häkkinen et al. reported the 
presence of benzodiazepines and alcohol in 82 % and 58 % of fatal 
buprenorphine poisonings, respectively (Häkkinen et al., 2012). In a 
Swedish study from 2005 to 2009, Seldén et al. reported 75 % of 
concomitant sedative/hypnotic drugs, 24 % of alcohol, and 2% pre-
gabalin in fatal buprenorphine poisonings (Seldén et al., 2012). The 
prevalence of benzodiazepines in our study was thus even higher than in 
previous studies. We also found that concomitant gabapentinoids, 
especially pregabalin (41 %), were prevalent; this reflects the increased 
popularity of gabapentinoids in supratherapeutic doses among people 
who use drugs (Evoy et al., 2017). One explanation for the high per-
centages observed in our study is that the concomitant drug use is based 
on comprehensive laboratory analysis (not limited to blood samples), 
rather than survey or prescription data. 
Interestingly, all buprenorphine user deaths in our material were 
strongly associated with polydrug use regardless of the cause of death 
(Fig. 3). Despite this, group A buprenorphine poisonings were charac-
terized by a significantly higher prevalence of alcohol, benzodiazepines, 
and gabapentinoids than the control group D. There were no corre-
sponding significant differences for the other types of drugs. In group A, 
we found a very low proportion of cases with only a single concomitant 
sedative/hypnotic drug present without other concomitant drugs; the 
percentages for benzodiazepines, alcohol, and gabapentinoids were 4%, 
1% and 0%, respectively. This finding highlights the extensive polydrug 
use in the study population. At the same time, polydrug use makes it 
impossible to estimate the contribution of specific sedative/hypnotics to 
death. 
Among individual benzodiazepine substances, the most prevalent 
findings in our study were clonazepam, alprazolam, and diazepam. The 
frequent occurrence of two or three individual benzodiazepine sub-
stances per death case suggests that a major proportion of the benzo-
diazepine findings is associated with medically non-supervised use. 
While prescribed benzodiazepines (especially oxazepam) are common in 
Finnish opioid use disorder patients, there are differences in the choice 
of the particular benzodiazepine between treatment facilities. Approxi-
mately a third of buprenorphine patients are prescribed benzodiaze-
pines, and up to another third regularly use benzodiazepines that are 
obtained illicitly (Park et al., 2020). As our study population is not 
limited to OAT patients, the much greater than two thirds proportion of 
benzodiazepine users is plausible. 
The large proportion of clonazepam detected in our study (53 % in 
group A) differed from a previous study in which clonazepam was 
detected only in 10 % (Seldén et al., 2012). There is currently a clear 
interest in clonazepam among people who use drugs (Høiseth et al., 
2015; Haukka et al., 2018). The ESCAPE Project 2017 on drug residues 
in used syringes from six European cities (EMCDDA, 2019b) showed that 
in the 284 syringes analyzed in Helsinki, Finland, the number of 
benzodiazepine-containing syringes was 32, as compared to 163 
buprenorphine findings and 150 findings for amphetamine or meth-
amphetamine. The most prevalent individual benzodiazepine was mid-
azolam in 15 syringes, while clonazepam and temazepam were the 
second-most prevalent in seven syringes each. These results suggest 
that users of buprenorphine mostly take benzodiazepines orally, 
whereas intravenous abuse of benzodiazepines is uncommon. The 
preference of midazolam over other benzodiazepines in intravenous use 
in the syringe residue study is probably due to the availability of a liquid 
midazolam formulation. 
Only three (1%) group A buprenorphine poisonings in our study 
population did not involve concurrent benzodiazepines, alcohol, or 
gabapentinoids. Among these cases, only Case 2 lacked toxicological 
findings other than buprenorphine. Case 1 showed toxic levels of MDMA 
and levomepromazine. Case 3 showed high levels of cannabis but the 
forensic pathologist had neither considered it to be the cause of death 
nor a contributing factor. Kriikku et al. found 1.3%–2.0% of cases 
without other psychoactive substances among deaths in which bupre-
norphine was the main cause of poisoning (Kriikku et al., 2018). Seldén 
et al., on the other hand, found up to 10 % of such cases (Seldén et al., 
2012). These percentages are certainly affected by the comprehensive-
ness of the laboratory analysis and by interpretations of the forensic 
pathologists. However, our findings confirm that fatal buprenorphine 
poisoning without interacting sedative/hypnotic drugs is a very rare 
phenomenon. 
We found an annually increasing number of deaths due to bupre-
norphine poisoning in young people during the study period. There were 
significantly more individuals aged 15–24 years in the buprenorphine 
poisoning group A than in any of the other groups. This finding may 
break the long-term trend in which age at death in fatal buprenorphine 
poisonings in Finland has been on the rise. The median age in group A 
was 31 years (20 % females), while the median age in buprenorphine 
poisonings during 2010–2014 was 33 years (Kriikku et al., 2018). Young 
age was significantly associated with more concomitant benzodiazepine 
and illicit drug use. The majority (65 %) of individuals aged 15–24 years 
died of fatal buprenorphine poisoning, whereas the cause of death in 
older age groups was more often unrelated to buprenorphine use. These 
findings may indicate more high-risk drug use among younger in-
dividuals, involving intravenous administration of buprenorphine and 
extensive and frequent polydrug use. 
The worsening of the drug situation in Finland was indeed evident in 
a recent study that examined the number and age of problem drug users. 
There were 31,100 to 44,300 high-risk users of amphetamines and 
opioids (27 % females) in Finland in 2017, which is 0.91%–1.29% 
(amphetamines 0.61− 0.81%, opioids 0.68− 0.86%) of Finns aged 15–64 
years. The number of high-risk opioid users had nearly doubled from a 
previous study in 2012, and there was a particular increase in the age 
group of 15–24 years (Rönkä et al., 2020). 
Despite guidelines that advise against additional prescription of 
drugs that may potentiate the respiratory depressive effects of opioids 
and increase risk of overdose death, these drugs are commonly pre-
scribed to opioid-dependent individuals (Zhu et al., 2018). Mcleod et al. 
studied the effects of prescription of benzodiazepines, z-drugs, and 
gabapentinoids amongst opioid-dependent patients receiving OAT in 
primary care (Macleod et al., 2019). The authors found that individuals 
that were additionally prescribed benzodiazepines had an increased risk 
of death from overdose, despite remaining in treatment longer. 
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Coprescription of z-drugs and gabapentinoids was also associated with 
increased mortality risk. However, for z-drugs there was no evidence for 
a dose-response effect on drug-related poisoning, and for gabapentinoids 
the increased mortality risk was not specific to drug-related poisoning. 
Park et al. pointed out that because benzodiazepines are associated with 
a decreased risk of OAT discontinuation and because OAT in turn is 
associated with significant reductions in overdose and mortality, pre-
scribing benzodiazepines may sometimes be justified if it results in the 
patient staying longer in treatment and thus staying alive (Park et al., 
2020). Kelty et al. compared blood toxicology in fatalities involving 
alcohol and other drugs in patients with an opioid use disorder treated 
with methadone, buprenorphine, and implant naltrexone. Their results 
indicated that the three medication groups had comparable suscepti-
bilities to lethal co-intoxication and that similar drug mixtures 
contributed to death (Kelty et al., 2020). 
In a recent study, Fugelstad et al. found that prescription opioid- and 
methadone-related deaths increased in the 15–29-year age group in 
Sweden between 2006 and 2015 (Fugelstad et al., 2020). Among the 269 
methadone-related deaths, thirty-eight (14 %) were attributed to 
methadone only. In 76 % of the cases, deaths occurred in those who had 
taken methadone while also using one or more benzodiazepines. Most 
methadone-related deaths occurred in individuals who were not pre-
scribed methadone. Despite the fact that, unlike buprenorphine, meth-
adone is a full agonist, there are many similarities in the deaths caused 
by these two opioids, such as delayed central respiratory depression, 
often in combination with other drugs, primarily benzodiazepines. 
On the basis of a Finnish survey, Launonen et al. stated that more 
effort should be made to reduce concurrent use of injectable drugs 
during OAT by addressing concurrent substance use orders more effec-
tively, by ensuring that patients receive an optimal buprenorphine/ 
naloxone dose, and by providing more psychosocial support (Launonen 
et al., 2016). Indeed, Heikman et al. found that inadequate doses of the 
OAT medicines (as experienced by the patients) were associated with 
higher subjective withdrawal scores, craving for opioids, and more 
common polydrug use (Heikman et al., 2017). 
Prevention of buprenorphine user deaths should focus on reducing 
concomitant use of alcohol, sedative/hypnotic drugs, and illicit drugs. 
However, this goal is difficult to achieve due to the addictive nature of 
the drug combination. There is clear evidence that persons with opioid 
use disorders rarely prefer buprenorphine for its inherent euphorigenic 
properties, but the drug is used to manage opioid withdrawal symptoms 
or to achieve or maintain abstinence from other opioids (Alho et al., 
2007; Cicero et al., 2014; Chilcoat et al., 2019). However, many persons 
with opioid use disorders use benzodiazepines to obtain or augment the 
opioid high in addition to using benzodiazepines for symptoms such as 
anxiety, insomnia, opioid withdrawal, and depression (Jones et al., 
2012; Stein et al., 2016). 
We regret to note that extensive concomitant use of benzodiazepines 
regardless of the cause of death masks nuanced drug interaction dif-
ferences between the buprenorphine user groups. The higher prevalence 
of concomitant benzodiazepines and illicit drugs and the higher mor-
tality in the age group 15–24 years than in older and more experienced 
users suggests particularly unsafe drug use patterns in the younger age 
group, which requires rapid intervention. Further research is needed to 
determine whether there are differences in risk between different indi-
vidual sedative/hypnotic drugs in concomitant use. Another area of 
interest is whether the route of administration of concomitant drugs or 
the order in which the opioid and sedative is taken is relevant to the fatal 
outcome. 
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